Juvenile idiopathic arthritis (JIA) is commonly managed with methotrexate (MTX), with many pediatric rheumatologists preferring to use parenteral MTX for compliance and absorption reasons.
All News
Cardiovascular events account for significant morbidity and mortality in patients with rheumatoid arthritis (RA) and other connnective tissue disorders (CTD). Investigators analyzed health records from a large U.S.
Patients with giant cell arteritis (GCA) had a higher rate of severe infections compared with the general population, a French study found.
The Arthritis Foundation announced that 11 scientists were selected out of 167 proposals as the 2015 Scientific Discovery Awardees for their innovations toward finding a cure for arthritis and related diseases.
A retrospective study examined mortality rates by comparing 2740 UK lupus patients who were matched 1:4 with controls from the UK Clinical Practice Research Datalink between 1999 and 2012. (Citation source http://buff.ly/1nJWKIT)
Althought EULAR currently recommends the pneumococcal vaccine be given to patients with inflammatory rheumatic diseases and the Centers for Disease Control and Prevention (CDC) recommends the vaccine in patients treated with immunosuppressive drugs, a recent brief report suggests it be
A Quebec administrative claims analysis examined the birth outcomes of women with a history of juvenile idiopathic arthritis (JIA) who subsequently had a first-time birth (between 1983-2010).
Until the advent of TNF inhibitor therapy, nonsteroidal antiinflammatory drugs (NSAIDs) were the only effective treatment for ankylosing spondylitis or spondyloarthritis (SpA). More recently, several reports have suggested clinical and radiographic benefits to sustained NSAID use.
Rheumatoid arthritis (RA) patients are said to have a neutral risk for neoplasia, but this is because they have a lower risk of colon cancer and breast cancer but a higher risk of lung cancer, lymphoma and skin cancers.
14-3-3η is a new serum assay that has utility in diagnosing and treating patients with rheumatoid arthritis (RA) and early inflammatory arthritis (EIA).
A Northern Sweden early rheumatoid arthritis (RA) cohort of 950 patients was enrolled starting in 1995. A validated questionnaire at RA onset (T0) and after 5 years (T5) after enrollment. Currently, 726 of these have had RA for ≥5 years.
A population-based study of 1,272,424 live-born infants from Denmark and Sweden examined the prevalence of birth defects among infants born to 683 women with chronic inflammatory disease (inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or psoriasis)
CT-P13, a biosimilar of infliximab (Remicade), demonstrated comparable and durable efficacy in the treatment of ankylosing spondylitis (AS), a multinational study found.
A recent report from the Mayo Clinic describes a 49 year-old patient with lupus nephritis who presented with new-onset hypertension, edema, arthritis, serositis and leukocytoclastic vasculitis, and who later developed glomerulonephritis and nephrotic syndrome.
A prospective study of 136 people who were CCP+, but who had no clinical evidence of synovitis, examined what factors may predict future development of inflammatory arthritis.
(Reuters Health) – Every year since 2006 in the U.S., the amount of new medical research in humans funded by the National Institutes of Health (NIH) has gone down, while the number of industry-funded trials has gone up, a new study shows.
In 2010, Smolen and a group of international rheumatologists developed a series of recommendations addressing the concept of treat-to-target (T2T) in the management of rheumatoid arthritis (RA).
Researchers from the DANBIO registry have linked their registry of 30,033 arthritis patients with the Danish Multiple Sclerosis Registry (DMSR) to identify all new multiple sclerosis cases occuring in arthritis patients and those receiving TNF inhibitors (TNFi).
Biosimilars are the fastest developing product line within the pharmaceutical industry. There is unanimous worldwide interest in the continued use of biologics for immune mediated disorders.
A national audit of rheumatoid arthritis (RA) and early inflammatory arthritis patients included 6,354 patients drawn from 143 trusts and health boards in England and Wales. Early arthritis clinics exist in 57% of trusts.
